Anthropic held its historic Nasdaq debut a day before Nvidia's stock closed out its longest weekly losing streak since 2008.
See storyResearch
Finance
The market pulse first, then top news and this week's notable earnings.
Market pulse
At a glance
Close, Fri Nov 20, 2026
as of Friday, November 20, 2026, at the market close (Eastern Time). Change versus the Thursday, Nov 19 close. Source: CNBC, confirmed against MarketWatch.
Leading
Lagging
Sector moves are Select Sector SPDR ETFs, close Fri Nov 20, 2026, also from CNBC. Leading is the three largest percentage gains or smallest losses. Lagging is the three largest declines.
Top news
The week in markets
Once the most valuable company in the world, Nvidia now ranks fourth behind Apple, Microsoft and Alphabet.
See story
Companies are shifting from share buybacks to stock issuance, adding new supply. Anthropic’s $81 billion IPO puts that demand to the test.
See story
Odds that the S&P 500 will cross 8,000, which were once north of 70%, are extremely low on platform Kalshi.
See story
Several stocks that are unpopular on Wall Street, including Clorox, Boston Beer and Campbell's, are poised to be winners as the AI trade loses steam.
See story
The Federal Reserve on Wednesday released minutes from its October policy meeting at which it voted to hold its benchmark interest rate in a range between 3.75%-4%.
See storyOur research
Briefings
Our own notes will appear here. The two cards below show the layout only. They are not published research.
Market briefing
No figures or findings are shown in this sample.
Research note
No figures or findings are shown in this sample.
This week
Earnings
Notable companies on the Nasdaq earnings calendar for the week of November 23, 2026, larger market caps only, up to four names a day. Times are listed as before the open or after the close when Nasdaq provides them.
Monday, November 23, 2026
Tuesday, November 24, 2026
Wednesday, November 25, 2026
Thursday, November 26, 2026
Friday, November 27, 2026
AI
AI news
Former Nvidia CEO Jensen Huang has faced a flurry of criticism on Capitol Hill in the wake of his involvement with a suspected Chinese spy.
See story
Biotech
Biotech news
The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines.
See story
The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.
See story
Compass and Usona are vying for an FDA first, but pricing, payer coverage and patient access could determine the commercial winner.
See story
Rasonque is already off to one of the best oncology launches in history. But certain limitations leave an opportunity that companies like Erasca — which is nearing the start of a Phase 3 trial — may be able to exploit.
See story
An ongoing shortage of Sanofi’s Pompe disease treatment is forcing some patients to miss critical doses. They worry their health is at risk.
See story
Wall Street analysts rushed to Celldex’s defense following the setback. Elsewhere, Isomorphic Labs cut a cancer-focused deal with Merck and Teva’s research chief accepted a new job.
See storyEnergy
Coming soon
News on energy will appear here.
Deals and IPOs
Coming soon
News on deals and IPOs will appear here.
Macro
Coming soon
News on macro will appear here.
Space and Defense
Coming soon
News on space and defense will appear here.
Crypto and Fintech
Coming soon
News on crypto and fintech will appear here.
Smart Money
Coming soon
News on smart money will appear here.
Startups
Coming soon
News on startups will appear here.